Social Media Listening for Routine Post-Marketing Safety Surveillance.
| Title: | Social Media Listening for Routine Post-Marketing Safety Surveillance. |
|---|---|
| Authors: | Powell GE; GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC, 27709, USA. gregory.e.powell@gsk.com.; Seifert HA; GlaxoSmithKline Vaccines, King of Prussia, PA, USA.; Reblin T; GlaxoSmithKline, Stockley Park, UK.; Burstein PJ; GlaxoSmithKline, King of Prussia, PA, USA.; Blowers J; GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC, 27709, USA.; Menius JA; GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC, 27709, USA.; Painter JL; GlaxoSmithKline, 5 Moore Dr., Research Triangle Park, NC, 27709, USA.; Thomas M; Blue Zone Industries, Chester Springs, PA, USA.; Pierce CE; Epidemico Inc., Boston, MA, USA.; Rodriguez HW; Epidemico Inc., Boston, MA, USA.; Brownstein JS; Epidemico Inc., Boston, MA, USA.; Freifeld CC; Epidemico Inc., Boston, MA, USA.; Bell HG; Zero Chaos, Research Triangle Park, NC, USA.; Dasgupta N; Epidemico Inc., Boston, MA, USA. |
| Source: | Drug safety [Drug Saf] 2016 May; Vol. 39 (5), pp. 443-54. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9002928 Publication Model: Print Cited Medium: Internet ISSN: 1179-1942 (Electronic) Linking ISSN: 01145916 NLM ISO Abbreviation: Drug Saf Subsets: MEDLINE |
| Imprint Name(s): | Publication: Auckland : Adis, Springer International; Original Publication: [Mairangi Bay, Auckland, N.Z. : ADIS Press Limited, c1990- |
| MeSH Terms: | Adverse Drug Reaction Reporting Systems* ; Social Media*; Drug-Related Side Effects and Adverse Reactions/*prevention & control ; Product Surveillance, Postmarketing/*methods; Databases, Factual ; Humans ; Information Storage and Retrieval ; Pharmacovigilance ; Research Report ; Safety |
| Abstract: | Introduction: Post-marketing safety surveillance primarily relies on data from spontaneous adverse event reports, medical literature, and observational databases. Limitations of these data sources include potential under-reporting, lack of geographic diversity, and time lag between event occurrence and discovery. There is growing interest in exploring the use of social media ('social listening') to supplement established approaches for pharmacovigilance. Although social listening is commonly used for commercial purposes, there are only anecdotal reports of its use in pharmacovigilance. Health information posted online by patients is often publicly available, representing an untapped source of post-marketing safety data that could supplement data from existing sources.; Objectives: The objective of this paper is to describe one methodology that could help unlock the potential of social media for safety surveillance.; Methods: A third-party vendor acquired 24 months of publicly available Facebook and Twitter data, then processed the data by standardizing drug names and vernacular symptoms, removing duplicates and noise, masking personally identifiable information, and adding supplemental data to facilitate the review process. The resulting dataset was analyzed for safety and benefit information.; Results: In Twitter, a total of 6,441,679 Medical Dictionary for Regulatory Activities (MedDRA(®)) Preferred Terms (PTs) representing 702 individual PTs were discussed in the same post as a drug compared with 15,650,108 total PTs representing 946 individual PTs in Facebook. Further analysis revealed that 26 % of posts also contained benefit information.; Conclusion: Social media listening is an important tool to augment post-marketing safety surveillance. Much work remains to determine best practices for using this rapidly evolving data source. |
| References: | Expert Opin Drug Saf. 2015;14(12):1845-53. (PMID: 26436834); Drug Saf. 2014 Oct;37(10):761-4. (PMID: 25096955); J Am Med Inform Assoc. 2013 May 1;20(3):446-52. (PMID: 23195749); J Med Internet Res. 2015 Jul 10;17(7):e171. (PMID: 26163365); Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1161-6. (PMID: 17486665); J Med Toxicol. 2013 Jun;9(2):184-91. (PMID: 23619711); J Biomed Inform. 2015 Apr;54:202-12. (PMID: 25720841); J Clin Pharm Ther. 2014 Feb;39(1):53-5. (PMID: 24304185); PLoS One. 2009 Nov 18;4(11):e7758. (PMID: 19924221); Drug Saf. 2011 Apr 1;34(4):267-71. (PMID: 21417499); Methods Inf Med. 2013;52(2):152-9. (PMID: 23450374); J Am Med Inform Assoc. 2013 May 1;20(3):404-8. (PMID: 23467469); PLoS Curr. 2015 Apr 28;7:null. (PMID: 25992303); Eur J Clin Pharmacol. 2013 Feb;69(2):209-15. (PMID: 22688722); Clin Pharmacol Ther. 2014 Aug;96(2):239-46. (PMID: 24713590); Expert Rev Clin Pharmacol. 2015 Jan;8(1):95-102. (PMID: 25487079); Br J Clin Pharmacol. 2015 Oct;80(4):910-20. (PMID: 26147850); Drug Saf. 2014 Aug;37(8):629-37. (PMID: 25027671); PLoS One. 2014 Oct 15;9(10):e110236. (PMID: 25333618); Drug Saf. 2014 May;37(5):343-50. (PMID: 24777653); J Biomed Inform. 2015 Feb;53:196-207. (PMID: 25451103); J Med Internet Res. 2014 Oct 15;16(10):e237. (PMID: 25591063); Ophthalmic Physiol Opt. 2014 Jan;34(1):46-52. (PMID: 24325434); Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1330-3. (PMID: 25250824); Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):3-8. (PMID: 24395545); J Intern Med. 2014 Jun;275(6):551-61. (PMID: 24635221); J Med Internet Res. 2015 Jun 08;17(6):e140. (PMID: 26054530); J Addict Dis. 2015;34(4):303-10. (PMID: 26364675); J Gen Intern Med. 2011 Mar;26(3):287-92. (PMID: 20945113); Br J Clin Pharmacol. 2015 Oct;80(4):878-88. (PMID: 26271492); J Biomed Inform. 2015 Apr;54:230-40. (PMID: 25688695); Drug Saf. 2007;30(6):551-4. (PMID: 17536881); J Am Med Inform Assoc. 2015 May;22(3):671-81. (PMID: 25755127); Pharmacoepidemiol Drug Saf. 2013 May;22(5):459-67. (PMID: 23208789); Drug Saf. 1999 Feb;20(2):95-107. (PMID: 10082068); Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):591-7. (PMID: 21538671); Ann Intern Med. 2010 Nov 2;153(9):600-6. (PMID: 21041580); Clin Pharmacol Ther. 2014 Aug;96(2):149-50. (PMID: 25056395); Drug Saf. 2015 Oct;38(10):921-30. (PMID: 26242616); Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903. (PMID: 24603135); Emerg Health Threats J. 2013 Nov 08;6:21621. (PMID: 24206612); Trends Pharmacol Sci. 2013 Jul;34(7):357-8. (PMID: 23759353); J Antimicrob Chemother. 2014 Sep;69(9):2568-72. (PMID: 24862092); AMIA Annu Symp Proc. 2014 Nov 14;2014:924-33. (PMID: 25954400); Am J Trop Med Hyg. 2012 Jan;86(1):39-45. (PMID: 22232449) |
| Entry Date(s): | Date Created: 20160123 Date Completed: 20161228 Latest Revision: 20181113 |
| Update Code: | 20260130 |
| DOI: | 10.1007/s40264-015-0385-6 |
| PMID: | 26798054 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't